[1] HIRSH J, FUSTER V, ANSELL J, et al.American heart association/American college of cardiology foundation guide to warfarin therapy[J]. Journal of the American College of Cardiology, 2003, 41(9): 1633-1652. [2] AGENO W, GALLUS AS, WITTKOWSKY A, et al.Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2): e44S-e88S. [3] LINKINS LA, CHOI PT, DOUKETIS JD.Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis[J]. Ann Intern Med, 2003, 139(11): 893-900. [4] KEARON C, AKL EA, COMEROTA AJ, et al.Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2): e419S-e496S. [5] ANSELL J, HIRSH J, Dalen J,et al.Managing oral anticoagulant therapy[J]. Chest, 2001, 119(1): 22s-38s. [6] KONSTANTINIDES SV, MEYER G, Becattini C, et al.2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)[J]. The European Respiratory Journal, 2019, 54(3): 1-68. [7] JANUARY CT, WANN LS, CALKINS H, et al.2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the society of thoracic surgeons[J]. Circulation, 2019, 140(2): e125-e151. [8] NISHIMURA RA, OTTO CM, BONOW RO, et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2017, 135(25): e1159-e1195. [9] CHIQUETTE E, AMATO MG, BUSSEY HI.Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs[J]. Arch Intern Med, 1998, 158(15): 1641-1647. [10] CHAMBERLAIN MA, SAGESER NA, RUIZ D.Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic[J]. J Am Board Fam Prac, 2001, 14(1): 16-21. [11] ZHOU S, SHENG XY, XIANG Q, et al.Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis[J]. Journal of Clinical Pharmacy and Therapeutics, 2016, 41(6): 602-611. [12] HOU K, YANG H, YE Z, et al.Effectiveness of pharmacist-led anticoagulation management on clinical outcomes: A systematic review and meta-analysis[J]. J pharm pharm sci, 2017, 20(1): 378-396. [13] KOSE E, AN T, KIKKAWA A.Assessment of oral anticoagulation control at pharmacist-managed clinics: A retrospective cohort study[J]. Die Pharmazie, 2018, 73(6): 356-360. [14] DU LP, LI Y, LI LL, et al.The impact of clinical pharmacy services on the quality of warfarin anticoagulation therapy management[J]. Chinese Pharmaceutical Journal, 2019, 54(9): 749-752. [15] MANZOOR BS, BAUMAN J, SHAPIRO NL, et al.Outcomes of systematic anticoagulation management in pharmacist and nurse specialized clinics[J]. Journal of the American College of Clinical Pharmacy, 2018, 1: 68-73. [16] YOSHII A, PLAUT DA, MCGRAW KA, et al.Analysis of the reporting of search strategies in Cochrane systematic reviews[J]. J Med Libr Assoc,2009, 97(1): 21-29. [17] STROUP DF, BERLIN JA, MORTON SC, et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting[J]. JAMA,2000, 283(15): 2008-2012. [18] HIGGINS JP, THOMPSON SG, DEEKS JJ, et al.Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-560. [19] AHMED NO, OSMAN B, ABDELHAI YM, et al.Impact of clinical pharmacist intervention in anticoagulation clinic in Sudan[J] . Int J Clin Pharm, 2017, 39(4): 769-773. [20] MIFSUD EM, WIRTH F, CAMILLERI L, et al.Pharmacist-led medicine use review in community pharmacy for patients on warfarin[J]. Int J Clin Pharm, 2019, 41(3): 741-750. [21] KATARUKA A, RENNER E, BARNES GD.Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management[J]. Hosp pract, 2018, 46(1): 16-21. [22] MCKENZIE JA, WILSON-CLARKE C, PROUT J, et al.Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica[J]. Pharm Pract (Granada), 2018, 16(4): 1214. [23] GRAY JA, LUGO RA, PATEL VN, et al.First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment[J]. J Thromb Thrombolysis, 2019, 48(4): 690-693. [24] JONES AE, KING JB, KIM K, et al.The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring[J]. J Thromb Thrombolysis, 2020, 50(3): 739-745. [25] ASHJIAN E, KURTZ B, RENNER E, et al.Evaluation of a pharmacist-led outpatient direct oral anticoagulant service[J]. Am J Health Syst Pharm, 2017, 74(7): 483-489. [26] FALAMIC S, LUCIJANIC M, HADZIABDIC MO, et al.Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial[J]. Int J Clin Pharm, 2018, 40(5): 1078-1085. [27] BUNGARD TJ, RITCHIE B, GARG S, et al.Sustained impact of anticoagulant control achieved in an anticoagulation management service after transfer of management to the primary care physician[J]. Pharmacotherapy, 2012, 32(2): 112-119. [28] LALONDE L, MARTINEAU J, BLAIS N, et al.Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial[J]. Am Heart J, 2008, 156(1): 148-154. [29] VERRET L, COUTURIER J, ROZON A, et al.Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial[J]. Pharmacotherapy, 2012, 32(10): 871-879. [30] JACKSON SL, PETERSON GM, VIAL JH, et al.Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation[J]. J Intern Med, 2004, 256(2): 137-144. [31] SCHILLIG J, KAATZ S, HUDSON M, et al.Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service[J]. J Hosp Med, 2011, 6(6): 322-328. [32] CHAN FW, WONG RS, LAU WH, et al.Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial[J]. Br J Clin Pharmacol, 2006, 62(5): 601-609. [33] WILSON SJ, WELLS PS, KOVACS MJ, et al.Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial[J]. CMAJ, 2003, 169(4): 293-298. [34] LAKSHMI R, JAMES E, KIRTHIVASAN R.Study on impact of clinical pharmacist’s interventions in the optimal use of oral anticoagulants in stroke patients[J]. Indian J Pharm Sci, 2013, 75(1): 53-59. [35] FALAMIC S, LUCIJANIC M, ORTNER HM, et al.Pharmacists’ influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients[J]. Int J Clin Pharm, 2019, 41(5): 1166-1173. [36] AN T, KOSE E, KIKKAWA A, et al.Hospital pharmacist intervention improves the quality indicator of warfarin control: A retrospective cohort study[J]. J Med Invest, 2017, 64(3): 266-271. [37] AIREE A, GUIRGUIS AB, MOHAMMAD RA.Clinical outcomes and pharmacists’acceptance of a community hospital’s anticoagulation management service utilizing decentralized clinical staff pharmacists[J]. Ann Pharmacother, 2009, 43(4): 621-628. [38] ELEWA H, JALALI F, KHUDAIR N, et al.Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar[J]. J Eval Clin Pract, 2016, 22(3): 433-438. [39] SARGENT R, BROCKLEBANK C, TAM TH, ET AL.Advantages of a warfarin protocol for long-term care pharmacists: a retrospective cohort study[J]. Can Geriatr J, 2016, 19(2): 40-49. [40] THANIMALAI S, SHAFIE AA, HASSALI MA, et al.Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital[J]. Int J Clin Pharm, 2013, 35(5): 736-743. [41] WITT DM, SADLER MA, SHANAHAN RL, et al.Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy[J]. Chest, 2005, 127(5): 1515-1522. [42] YOUNG S, BISHOP L, TWELLS L, et al.Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic[J]. BMC Fam Pract, 2011, 12: 88. [43] MARTIN CY, HERMANN SA, COULDRY RJ.Impact of pharmacist-managed warfarin on patient outcomes in an academic medical center[J]. Am J Health Syst Pharm, 2015, 72(11): S31. [44] HALL D, BUCHANAN J, HELMS B, ET AL.Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care[J]. Pharmacotherapy, 2011, 31(7): 686-694. [45] SAOKAEW S, PERMSUWAN U, CHAIYAKUNAPRUK N, et al.Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis[J]. J Thrombo Haemost, 2010, 8(11): 2418-2427. [46] TAJER C, CERESETTO J, BOTTARO FJ, et al.Assessment of the quality of chronic anticoagulation control with time in therapeutic range in atrial fibrillation patients treated with vitamin K antagonists by hemostasis specialists: the TERRA registry: tiempo en rango en la republica Argentina[J]. Clin Appl Thromb hemost, 2017, 23(5): 445-453. [47] VESTERGAARD AS, SKJOTH F, LARSEN TB, et al.The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis[J]. PloS one, 2017, 12(11): e0188482. [48] SOLVIK UO, LOKKEBO ES, KRISTOFFERSEN AH, et al.Self-management of warfarin therapy[J]. Tidsskr Nor Laegeforen, 2015, 135(9): 849-853. [49] MA ZY, CHENG G, WANG P, et al.Clinical model for predicting warfarin sensitivity[J]. Sci Rep, 2019, 9(1): 12856. [50] LIMDI NA, WADELIUS M, CAVALLARI L, et al.Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups[J]. Blood, 2010, 115(18): 3827-3834. [51] JOHNSON JA, CAVALLARI LH.Warfarin pharmacogenetics[J]. Trends Cardiovasc Med, 2015, 25(1): 33-41. [52] JOHNSON JA, CAUDLE KE, GONG L, et al.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update[J]. Clin Pharmacol Ther, 2017, 102(3): 397-404. [53] GUPTA V, KOGUT SJ, Thompson S.Evaluation of differences in percentage of international normalized ratios in range between pharmacist-led and physician-led anticoagulation management services[J]. J Pharm Pract, 2015, 28(3): 249-255. |